12:00 AM
 | 
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ilaris: Preliminary Phase II data

Preliminary data from a double-blind Phase II trial in 432 patients who were initiating allopurinol therapy showed that single subcutaneous injections of 25, 50, 100, 200 and 300 mg canakinumab and 150 mg canakinumab dosed over 4 weeks significantly reduced the rate of acute gout flares vs. colchicine at 16 weeks (p<=0.05 for all). Canakinumab also significantly reduced the...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >